Status:
COMPLETED
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Hepatitis C
Eligibility:
All Genders
18-49 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the effect of BMS-791325 on the pharmacokinetics of the CYP3A4 Probe Midazolam.
Eligibility Criteria
Inclusion
- Healthy male and female subjects aged 18 to 49 years, with BMI of 18-32 kg/m²
- Women who are not of childbearing potential
Exclusion
- Women of childbearing potential
- Women who are pregnant, breastfeeding, or unwilling or unable to use an acceptable method of birth control.
- Gastrointestinal disease that may impact the absorption of study drug
- History of any chronic respiratory disease (asthma, COPD)
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00996879
Start Date
May 1 2013
End Date
September 1 2013
Last Update
May 6 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wcct Global, Llc
Cypress, California, United States, 90630